Abstract CT226: A Phase I trial ofin situvaccination with autologousCCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct226
Abstract: Background: The majority of NSCLC patients do not respond to single agent PD-1/PD-L1 inhibitors, in part due to the lack of cytolytic T cell infiltration at the tumor site. To improve the efficacy of checkpoint… read more here.
Keywords: ccl21; phase trial; combined pembrolizumab; cell ... See more keywords